Immunoadsorption in nephrology and kidney transplantation

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2407-2413

  Schwenger, Vedat ^a   Morath, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

autoimmune disorders; immunoadsorption; plasmapheresis; transplantation

Indexed keywords

AGGLUTININ; ALBUMIN; ALLOANTIBODY; CYCLOPHOSPHAMIDE; DEXTRAN SULFATE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTROPHIL CYTOPLASMIC ANTIBODY; PHENYLALANINE; PROTEIN A; RITUXIMAB; SEPHAROSE; TRYPTOPHAN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BLOOD GROUP ABO INCOMPATIBILITY; CRYOGLOBULINEMIA; DEVICE; FOCAL GLOMERULOSCLEROSIS; GOODPASTURE SYNDROME; GRAFT RECIPIENT; GRAFT REJECTION; HLA SYSTEM; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIGAND BINDING; NEPHROLOGY; NOTE; PLASMAPHERESIS; PRIORITY JOURNAL; SMALL VESSEL VASCULITIS; SYSTEMATIC DESENSITIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; KIDNEY DISEASES; PROCEDURES;

GRAFT REJECTION; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSUPPRESSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION;

EID: 77954764231     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq264     Document Type: Note

References (63)

1. Belak M, Borberg H, Jimenez C et al. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sci 1994; 15: 419-422
2. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935
3. Schneider KM. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. Kidney Int Suppl 1998; 64: S61-S65
4. Gjorstrup P, Berntorp E, Larsson L et al. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immu- noadsorption. Vox Sang 1991; 61: 244-250
5. Feld SM, Figueroa P, Savin V et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998; 32: 230-237
6. Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylat- ing agents: does it benefit patients with focal segmental glomerulo- sclerosis? Nephrol Dial Transplant 1998; 13: 1524-1528
7. Godfrin Y, Dantal J, Bouhours JF et al. A new method of measuring albumin permeability in isolated glomeruli. Kidney Int 1996; 50: 1352-1357 (Pubitemid 26342828)
8. Haas M, Godfrin Y, Oberbauer R et al. Plasma immunoadsorption treatment in patients with primary focal and segmental glomerulo- sclerosis. Nephrol Dial Transplant 1998; 13: 2013-2016
9. Mannik M, Merrill CE, Stamps LD et al. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1495-1504
10. Lewis EJ, Hunsicker LG, Lan SP et al. A controlled trial of plasma- pheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326: 1373-1379
11. Gaubitz M, Seidel M, Kummer S et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythema- tosus. JAutoimmun 1998; 11: 495-501
12. Stummvoll GH, Aringer M, Smolen JS et al. IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 2005; 64: 1015-1021
13. Dittrich E, Schmaldienst S, Langer M et al. Immunoadsorption and plasma exchange in pregnancy. Kidney Blood Press Res 2002; 25: 232-239
14. Pagnoux C, Korach JM, Guillevin L. Indications for plasma exchange in systemic lupus erythematosus in 2005. Lupus 2005; 14: 871-877
15. Falk RJ, Jennette JC. ANCA are pathogenic-oh yes they are! J Am Soc Nephrol 2002; 13: 1977-1979
16. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006; 17: 1235-1242
17. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188
18. Nakamura T, Matsuda T, Kawagoe Y et al. Plasmapheresis with immunosuppressive therapy vs immunosuppressive therapy alone for rapidly progressive anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Nephrol Dial Transplant 2004; 19: 1935-1937
19. Pusey CD, Rees AJ, Evans DJ et al. Plasma exchange in focal nec- rotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-763
20. Aasarod K, Iversen BM, Hammerstrom J et al. Clinical outcome of patients with Wegener's granulomatosis treated with plasma exchange. Blood Purif 2002; 20: 167-173
21. Koch M, Kohnle M, Trapp R. A case report of successful long-term relapse control by protein-a immunoadsorption in an immunosup- pressive-treated patient with end-stage renal disease due to Wegener's granulomatosis. Ther Apher Dial 2009; 13: 150-156
22. Matic G, Michelsen A, Hofmann D et al. Three cases of C-ANCA- positive vasculitis treated with immunoadsorption: possible benefit in early treatment. Ther Apher 2001; 5: 68-72
23. Stegmayr BG, Almroth G, Berlin G et al. Plasma exchange or immu- noadsorption in patients with rapidly progressive crescentic glomer- ulonephritis. A Swedish multi-center study. Int JArtif Organs 1999; 22: 81-87
24. Johnson JP, Whitman W, Briggs WA et al. Plasmapheresis and immunosuppressive agents in antibasement membrane antibody- induced Goodpasture's syndrome. Am J Med 1978; 64: 354-359
25. Levy JB, Turner AN, Rees AJ et al. Long-term outcome of anti- glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134: 1033-1042
26. Lockwood CM, Rees AJ, Pearson TA et al. Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome. Lancet 1976; 1: 711-715
27. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973; 3: 74-89
28. Esnault VL, Testa A, Jayne DR et al. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1993; 65: 180-184
29. Hu W, Liu Z, Ji D et al. Staphylococcal protein A immunoadsorption for Goodpasture's syndrome in four Chinese patients. J Nephrol 2006; 19: 312-317
30. Bolton WK. Goodpasture's syndrome. Kidney Int 1996; 50: 1753-1766
31. Takahashi K, Saito K, Takahara S et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4: 1089-1096
32. Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-1322
33. Tyden G, Kumlien G, Genberg H et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immu- noadsorption and rituximab. Am J Transplant 2005; 5: 145-148
34. Donauer J, Wilpert J, Geyer M et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a single center experience. Xenotransplantation 2006; 13: 108-110
35. Haidinger M, Schmaldienst S, Kormoczi G et al. Vienna experience of ABO-incompatible living-donor kidney transplantation. Wien Klin Wochenschr 2009; 121: 247-255
36. Genberg H, Kumlien G, Wennberg L et al. Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab. Transplantation 2007; 84: S44-S47
37. Tyden G, Donauer J, Wadstrom J et al. Implementation of a Protocol for ABO-incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations. Transplantation 2007; 83: 1153-1155
38. Valli PV, Puga Yung G, Fehr T et al. Changes of circulating antibody levels induced by ABO antibody adsorption for ABO-incompatible kidney transplantation. Am J Transplant 2009; 9: 1072-1080
39. Stegall MD, Gloor J, Winters JL et al. A comparison of plasmapher- esis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351
40. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-251
41. Bevan DJ, Carey BS, Vaughan RW et al. Anticipation of highly sensitised renal patients' immunoadsorption requirements by pre- screening using protein A minicolumns. Transpl Int 1996; 9: S20-S24
42. Hakim RM, Milford E, Himmelfarb J et al. Extracorporeal removal of anti-HLA antibodies in transplant candidates. Am J Kidney Dis 1990; 16: 423-431
43. Higgins RM, Bevan DJ, Carey BS et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208-1211
44. Haas M, Bohmig GA, Leko-Mohr Z et al. Peri-operative immunoad- sorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17: 1503-1508
45. Lorenz M, Regele H, Schillinger M et al. Peritransplant immunoad- sorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79: 696-701
46. Beimler JH, Morath C, Schmidt J et al. Successful deceased-donor kidney transplantation in crossmatch-positive patients with peri- transplant plasma exchange and rituximab. Transplantation 2009; 87: 668-671
47. Billing H, Rieger S, Ovens J et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86: 1214-1221
48. Fehr T, Rusi B, Fischer A et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837-1841
49. Bohmig GA, Regele H, Exner M et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 2482-2489
50. Bohmig GA, Wahrmann M, Regele H et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7: 117-121
51. Stummvoll GH, Aringer M, Jansen M et al. Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. WienKlin Wochenschr 2004; 116: 716-724
52. Schmaldienst S, Jansen M, Hollenstein U et al. Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. Am J Kidney Dis 2002; 39: 415-418
53. Schmaldienst S, Mullner M, Goldammer A et al. Intravenous im- munoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford) 2001; 40: 513-521
54. Braun N, Gutenberger S, Erley CM et al. Immunoglobulin and circulating immune complex kinetics during immunoadsorption onto protein A sepharose. Transfus Sci 1998; 19: 25-31
55. Stefanutti C, Vivenzio A, Di Giacomo S et al. Cyclophosphamide and immunoadsorption apheresis treatment of lupus nephritis nonre- sponsive to drug therapy alone. BioDrugs 2005; 19: 129-133
56. Braun N, Junger M, Klein R et al. Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus. Ther Apher 2002; 6: 471-477
57. Suzuki K. The role of immunoadsorption using dextran-sulfate cellulose columns in the treatment of systemic lupus erythematosus. Ther Apher 2000; 4: 239-243
58. Suzuki K, Hara M, Harigai M et al. Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus. Arthritis Rheum 1991; 34: 1546-1552
59. Hashimoto H, Tsuda H, Kanai Y et al. Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythemato- sus. J Rheumatol 1991; 18: 545-551
60. Sugimoto K, Yamaji K, Yang KS et al. Immunoadsorption plasma- pheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial 2006; 10: 187-192
61. Schneider M, Gaubitz M, Perniok A. Immunoadsorption in systemic connective tissue diseases and primary vasculitis. Ther Apher 1997; 1: 117-120
62. Hiepe F, Pfuller B, Wolbart K et al. C1q: a multifunctional ligand for a new immunoadsorption treatment. Ther Apher 1999; 3: 246-251
63. Stummvoll G. Immunadsorption beim systemischen Lupus. Nephro- Script 2007; 2: 34-37